Abstract
Purpose
To assess and compare the value of psoas muscle thickness at the level of the third lumbar (L3) vertebra (TPML) or umbilicus (TPMU) and skeletal muscle index (SMI) for diagnosing sarcopenia and predicting mortality in patients undergoing transjugular intrahepatic portosystemic shunt (TIPS).
Materials and Methods
Two hundred forty-nine patients undergoing TIPS were included in this retrospective study. The cut-offs of L3-SMI for sarcopenia were 42.0 cm2/m2 in men and 38.0 cm2/m2 in women. The cut-offs for TPML/height and TPMU/height to predict mortality was established using a receiver-operating characteristic analysis. The Kaplan–Meier and Cox regression were used for survival analyses.
Results
Compared with TPMU/height, TPML/height was more consistent with L3-SM for the diagnosis of sarcopenia (Kappa coefficient: 0.63 vs. 0.36 in men; 0.61 vs. 0.45 in women). The Cox analysis showed that both TPML/height and TPMU/height were independent risk factors for mortality. The optimal cut-off values of TPML/height and TPMU/height for mortality in men and women were 11.2 mm/m, 9.4 mm/m, 18.4 mm/m, 15.1 mm/m, respectively. There were 119 (47.8%), 87 (34.9%), and 82 (32.9%) patients diagnosed with sarcopenia in the TPMU/height, TPML/height, and L3-SMI models, respectively. Kaplan–Meier analysis showed that the overall survival was significantly lower in the sarcopenia group in all three models.
Conclusion
TPMU/height and TPML/height have a similar survival prognostic value as L3-SMI. TPML/height has better consistency with L3-SMI in diagnosing sarcopenia and is a more stable alternative to L3-SMI for diagnosing sarcopenia in patients undergoing TIPS.





References
Lai JC, Tandon P, Bernal W et al. Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 practice guidance by the american association for the study of liver diseases. Hepatology. 2021;74:1611–1644.
Kim SE, Kim DJ. Sarcopenia as a prognostic indicator of liver cirrhosis. J Cachexia Sarcopenia Muscle. 2022;13:8–10.
Tantai X, Liu Y, Yeo YH et al. Effect of sarcopenia on survival in patients with cirrhosis: a meta-analysis. J Hepatol. 2022;76:588–599.
Tapper EB, Zhang P, Garg R et al. Body composition predicts mortality and decompensation in compensated cirrhosis patients: a prospective cohort study. JHEP Rep. 2020;2:100061.
Ando Y, Ishigami M, Ito T et al. Sarcopenia impairs health-related quality of life in cirrhotic patients. Eur J Gastroenterol Hepatol. 2019;31:1550–1556.
Montano-Loza AJ, Meza-Junco J, Prado CMM et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol. 2012;10:166-U164.
Liu J, Ma J, Yang C et al. Sarcopenia in patients with cirrhosis after transjugular intrahepatic portosystemic shunt placement. Radiology. 2022;303:711–719.
Bureau C, Thabut D, Oberti F et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology. 2017;152:157–163.
Praktiknjo M, Clees C, Pigliacelli A et al. Sarcopenia is associated with development of acute-on-chronic liver failure in decompensated liver cirrhosis receiving transjugular intrahepatic portosystemic shunt. Clin Transl Gastroenterol. 2019;10:e00025.
Ronald J, Bozdogan E, Zaki IH et al. Relative sarcopenia with excess adiposity predicts survival after transjugular intrahepatic portosystemic shunt creation. AJR Am J Roentgenol 2020;214:200–205.
Nardelli S, Lattanzi B, Torrisi S et al. Sarcopenia is risk factor for development of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt placement. Clin Gastroenterol Hepatol. 2017;15:934–936.
Artru F, Miquet X, Azahaf M et al. Consequences of TIPSS placement on the body composition of patients with cirrhosis and severe portal hypertension: a large retrospective ct-based surveillance. Aliment Pharmacol Ther. 2020;52:1516–1526.
Tsien C, Shah SN, Mccullough AJ et al. Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent. Eur J Gastroenterol Hepatol. 2013;25:85–93.
Topan MM, Sporea I, Danila M et al. Impact of sarcopenia on survival and clinical outcomes in patients with liver cirrhosis. Front Nutr. 2021;21:766451.
Sinclair M, Gow PJ, Grossmann M et al. Review article: Sarcopenia in cirrhosis–aetiology, implications and potential therapeutic interventions. Aliment Pharmacol Ther. 2016;43:765–777.
Gu DH, Kim MY, Seo YS et al. Clinical usefulness of psoas muscle thickness for the diagnosis of sarcopenia in patients with liver cirrhosis. Clin Mol Hepatol. 2018;24:319–330.
Ebadi M, Wang CW, Lai JC et al. Poor performance of psoas muscle index for identification of patients with higher waitlist mortality risk in cirrhosis. J Cachexia Sarcopenia Muscle. 2018;9:1053–1062.
Durand F, Buyse S, Francoz C et al. Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography. J Hepatol. 2014;60:1151–1157.
Young S, Rostambeigi N, Golzarian J et al. MELD or sodium MELD: a comparison of the ability of two scoring systems to predict outcomes after transjugular intrahepatic portosystemic shunt placement. AJR Am J Roentgenol. 2020;215:215–222.
Tripathi D, Stanley AJ, Hayes PC et al. Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension. Gut. 2020;69:1173–1192.
Zeng X, Shi ZW, Yu JJ et al. Sarcopenia as a prognostic predictor of liver cirrhosis: a multicentre study in china. J Cachexia Sarcopeni. 2021;12:1948–1958.
Kong M, Geng N, Zhou Y et al. Defining reference values for low skeletal muscle index at the L3 vertebra level based on computed tomography in healthy adults: a multicentre study. Clin Nutr. 2022;41:396–404.
Nishikawa H, Shiraki M, Hiramatsu A et al. Japan society of hepatology guidelines for sarcopenia in liver disease (1st edition): recommendation from the working group for creation of sarcopenia assessment criteria. Hepatol Res. 2016;46:951–963.
Delong ER, Delong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837–845.
European Association for the Study of The Liver. EASL clinical practice guidelines on nutrition in chronic liver disease. J Hepatol. 2019;70:172–193.
Lee JT. Sarcopenia at abdominal CT in patients with cirrhosis. Radiology. 2022;303:720–721.
Paternostro R, Lampichler K, Bardach C et al. The value of different CT-based methods for diagnosing low muscle mass and predicting mortality in patients with cirrhosis. Liver Int. 2019;39:2374–2385.
Kim TY, Kim MY, Sohn JH et al. Sarcopenia as a useful predictor for long-term mortality in cirrhotic patients with ascites. J Korean Med Sci. 2014;29:1253–1259.
Englesbe MJ, Patel SP, He K et al. Sarcopenia and mortality after liver transplantation. J Am Coll Surg. 2010;211:271–278.
Ozola-Zālīte I, Frøkjær JB, Mark EB et al. A clinical feasible method for computed tomography-based assessment of sarcopenia in patients with chronic pancreatitis. Pancreas. 2019;48:1354–1359.
Vivian L, Omeed A, Tapas T et al. P017 sarcopenia defined by psoas muscle thickness is not a predictor of post-operative outcomes in IBD patients. Am J Gastroenterol. 2020;115:S4–S5.
Praktiknjo M, Book M, Luetkens J et al. Fat-free muscle mass in magnetic resonance imaging predicts acute-on-chronic liver failure and survival in decompensated cirrhosis. Hepatology. 2018;67:1014–1026.
Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol. 2018;68:268–279.
Funding
This work was supported by National Natural Science Foundation of China (grant number: 81873917).
Author information
Authors and Affiliations
Contributions
BX, TL and JL conceived and designed the study. YB, YW, SH, CW, SJ and WY collected the data. TL, CY and YC analyzed all data. JL and TL drafted the manuscript. BX and JZ revised the final manuscript. All authors have read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors of this manuscript declare that they have no conflicts of interest.
Research involving human participants and/or animals
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This retrospective study was approved by the institutional review board of the Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.
Consent for publication
Not applicable.
Informed consent
As a retrospective analysis, informed consent in this study was waived.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Li, T., Liu, J., Zhao, J. et al. Sarcopenia Defined by Psoas Muscle Thickness Predicts Mortality After Transjugular Intrahepatic Portosystemic Shunt. Dig Dis Sci 68, 1641–1652 (2023). https://doi.org/10.1007/s10620-022-07806-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-022-07806-z